Literature DB >> 30125602

Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.

Aditya Barve1, Lavona Casson2, Maxwell Krem3, Mark Wunderlich4, James C Mulloy4, Levi J Beverly5.   

Abstract

Cell-line-derived xenografts (CDXs) or patient-derived xenografts (PDXs) in immune-deficient mice have revolutionized our understanding of normal and malignant human hematopoiesis. Transgenic approaches further improved in vivo hematological research, allowing the development of human-cytokine-producing mice, which show superior human cell engraftment. The most popular mouse strains used in research, the NOG (NOD.Cg-Prkdcscid Il2rγtm1Sug/Jic) and the NSG (NOD/SCID-IL2Rγ-/-, NOD.Cg-PrkdcscidIl2rγtm1Wjl/SzJ) mouse, and their human-cytokine-producing (interleukin-3, granulocyte-macrophage colony-stimulating factor, and stem cell factor) counterparts (huNOG and NSGS), rely partly on a mutation in the DNA repair protein PRKDC, causing a severe combined immune deficiency (SCID) phenotype and rendering the mice less tolerant to DNA-damaging therapeutics, thereby limiting their usefulness in the investigation of novel acute myeloid leukemia (AML) therapeutics. NRG (NOD/RAG1/2-/-IL2Rγ-/-) mice show equivalent immune ablation through a defective recombination activation gene (RAG), leaving DNA damage repair intact, and human-cytokine-producing NRGS (NRG-SGM3) mice were generated, improving myeloid engraftment. Our findings indicate that unconditioned NRG and NRGS mice can harbor established AML CDXs and can tolerate aggressive induction chemotherapy at higher doses than NSG mice without overt toxicity. However, unconditioned NRGS mice developed less clinically relevant disease, with CDXs forming solid tumors throughout the body, whereas unconditioned NRG mice were incapable of efficiently supporting PDX or human hematopoietic stem cell engraftment. These findings emphasize the contextually dependent utility of each of these powerful new strains in the study of normal and malignant human hematopoiesis. Therefore, the choice of mouse strain cannot be random, but must be based on the experimental outcomes and questions to be addressed.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30125602      PMCID: PMC6200600          DOI: 10.1016/j.exphem.2018.08.004

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  33 in total

Review 1.  Targeting the microenvironment in acute myeloid leukemia.

Authors:  Armin Rashidi; Geoffrey L Uy
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

2.  'Nude', a new hairless gene with pleiotropic effects in the mouse.

Authors:  S P Flanagan
Journal:  Genet Res       Date:  1966-12       Impact factor: 1.588

3.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 4.  The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID.

Authors:  K Sugamura; H Asao; M Kondo; N Tanaka; N Ishii; K Ohbo; M Nakamura; T Takeshita
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 5.  Mouse models of advanced spontaneous metastasis for experimental therapeutics.

Authors:  Giulio Francia; William Cruz-Munoz; Shan Man; Ping Xu; Robert S Kerbel
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

Review 6.  Current advances in humanized mouse models.

Authors:  Ryoji Ito; Takeshi Takahashi; Ikumi Katano; Mamoru Ito
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

7.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

8.  AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.

Authors:  Mark Wunderlich; Benjamin Mizukawa; Fu-Sheng Chou; Christina Sexton; Mahesh Shrestha; Yogen Saunthararajah; James C Mulloy
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

Review 9.  Beyond DNA repair: DNA-PK function in cancer.

Authors:  Jonathan F Goodwin; Karen E Knudsen
Journal:  Cancer Discov       Date:  2014-08-28       Impact factor: 39.397

Review 10.  'Acute myeloid leukemia: a comprehensive review and 2016 update'.

Authors:  I De Kouchkovsky; M Abdul-Hay
Journal:  Blood Cancer J       Date:  2016-07-01       Impact factor: 11.037

View more
  9 in total

Review 1.  Understanding Normal and Malignant Human Hematopoiesis Using Next-Generation Humanized Mice.

Authors:  Yoriko Saito; Leonard D Shultz; Fumihiko Ishikawa
Journal:  Trends Immunol       Date:  2020-07-03       Impact factor: 16.687

2.  Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia.

Authors:  Kanak Joshi; Lei Zhang; Peter Breslin S J; Jiwang Zhang
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 3.650

Review 3.  Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications.

Authors:  Nathaniel A Long; Upendarrao Golla; Arati Sharma; David F Claxton
Journal:  Stem Cell Rev Rep       Date:  2022-01-20       Impact factor: 6.692

4.  Improved chemotherapy modeling with RAG-based immune deficient mice.

Authors:  Mark Wunderlich; Nicole Manning; Christina Sexton; Anthony Sabulski; Luke Byerly; Eric O'Brien; John P Perentesis; Benjamin Mizukawa; James C Mulloy
Journal:  PLoS One       Date:  2019-11-20       Impact factor: 3.240

Review 5.  Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates.

Authors:  Magdalena Cybula; Magdalena Bieniasz
Journal:  Oncotarget       Date:  2022-03-24

Review 6.  In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts.

Authors:  Eric P Souto; Lacey E Dobrolecki; Hugo Villanueva; Andrew G Sikora; Michael T Lewis
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-06-13       Impact factor: 2.698

7.  Development of Mast Cell and Eosinophil Hyperplasia and HLH/MAS-Like Disease in NSG-SGM3 Mice Receiving Human CD34+ Hematopoietic Stem Cells or Patient-Derived Leukemia Xenografts.

Authors:  Laura J Janke; Denise M Imai; Heather Tillman; Rosalinda Doty; Mark J Hoenerhoff; Jiajie J Xu; Zachary T Freeman; Portia Allen; Natalie Wall Fowlkes; Ilaria Iacobucci; Kirsten Dickerson; Charles G Mullighan; Peter Vogel; Jerold E Rehg
Journal:  Vet Pathol       Date:  2020-11-19       Impact factor: 2.221

8.  Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.

Authors:  Aditya Barve; Alexis Vega; Parag P Shah; Smita Ghare; Lavona Casson; Mark Wunderlich; Leah J Siskind; Levi J Beverly
Journal:  Cells       Date:  2019-10-25       Impact factor: 6.600

9.  Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research.

Authors:  Magdalena Cybula; Lin Wang; Luyao Wang; Ana Luiza Drumond-Bock; Katherine M Moxley; Doris M Benbrook; Camille Gunderson-Jackson; Maria J Ruiz-Echevarria; Resham Bhattacharya; Priyabrata Mukherjee; Magdalena Bieniasz
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.